Clinical Trials
11 trialsNCT07560410 2026-05-11
Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)
China Medical University Hospital
Phase 1/2 Not yet recruiting
NCT03202940 2026-05-08
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT04774718 2026-05-05
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05713006 2026-04-08
Alectinib Pharmacokinetic in Patients With NSCLC
Instituto Nacional de Cancerologia de Mexico
Phase 1/2 Recruiting
NCT05987644 2026-04-08
DURABLE
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT06624059 2026-04-08
HORIZON 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT03131206 2021-09-27
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01801111 2018-11-02
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Hoffmann-La Roche
Phase 1/2 Completed
NCT01871805 2018-08-21
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 1/2 Completed